Is Amphastar P (AMPH) overvalued? · P/E 12, rev $732.0M
Amphastar P (AMPH) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page asks whether Amphastar P (AMPH) looks expensive on cached numbers — not a short thesis.
Latest reported AMPH revenue for 2024-12-31 was $732.0M. Net income was $159.5M. Revenue was up 13.6% from 2023-12-31 to 2024-12-31. AMPH currently screens at market cap $880.1M and trailing P/E 12.0.
AMPH currently screens at market cap $880.1M and trailing P/E 12.0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AMPH 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AMPH stock page for the full model, not this heading.
Not investment advice.